Growth of short normal children in puberty treated for 3 years with growth hormone alone or in association with gonadotropin-releasing hormone agonist.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Triptorelin in this randomized controlled trial publication.

There were 16 males, aged 14.4 +/- 0.8 years, and 14 females, aged 12.2 +/- 1.2 years, at pubertal stage 2 or 3 with slow growth (4.2 +/- 1.2 cm/year) and no detected GH insufficiency or other cause for short stature.

Who Took Part

According to the abstract, 30 patients were involved.

The age groups tagged for this paper are children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

PubMed files the paper under topics including Age Determination by Skeleton, Body Height, Growth, Growth Disorders, Growth Hormone, Insulin-Like Growth Factor I and Puberty.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Triptorelin in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1994 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Triptorelin compound page, all human trials.